Compare CECO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CECO | SUPN |
|---|---|---|
| Founded | 1966 | 2005 |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | N/A | 2012 |
| Metric | CECO | SUPN |
|---|---|---|
| Price | $66.78 | $48.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.67 | $61.60 |
| AVG Volume (30 Days) | 243.6K | ★ 728.0K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 334.15 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $718,253,000.00 | $681,539,000.00 |
| Revenue This Year | $39.58 | $8.18 |
| Revenue Next Year | $14.60 | $22.15 |
| P/E Ratio | $49.57 | ★ N/A |
| Revenue Growth | ★ 29.86 | 4.54 |
| 52 Week Low | $17.57 | $29.16 |
| 52 Week High | $71.69 | $57.65 |
| Indicator | CECO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 46.43 |
| Support Level | $66.66 | $47.29 |
| Resistance Level | $71.66 | $49.71 |
| Average True Range (ATR) | 2.61 | 1.45 |
| MACD | -0.29 | -0.21 |
| Stochastic Oscillator | 22.06 | 30.10 |
CECO Environmental Corp serves the energy, industrial, and other niche markets. The company operates through the Engineered Systems segment that serves the power generation, refinery, water/wastewater, and midstream oil and gas markets, and Industrial Process Solutions segment, which serves the broad industrial air pollution control, beverage can, fluid handling, electric vehicle production, food and beverage, semi-conductor, process filtration, pharmaceutical, petrochemical, wastewater treatment, wood manufacturing, desalination, and aquaculture markets. The majority of revenue is earned from the Engineered Systems Segment.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.